weekly_roundup
BioTechSign Daily Catalyst Roundup - October 27, 2026
Top BioTechSign catalyst names today: ITCI, DCPH, BGNE, AKBA, RGNX, SRPT. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisOctober 27, 2026
Daily Biotech Catalyst Digest: October 27, 2026
ITCI leads the current BioTechSign screen at 100.0/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| ITCI | Intra-Cellular Therapies | 100.0 | A | clinical activity 100% |
| DCPH | Deciphera Pharmaceuticals | 100.0 | A | clinical activity 100% |
| BGNE | BeiGene Ltd | 100.0 | A | publication signal 100%, clinical activity 100% |
| AKBA | Akebia Therapeutics | 87.2 | A | clinical activity 92%, short interest 50% |
| RGNX | REGENXBIO Inc | 86.4 | A | publication signal 100%, clinical activity 100%, short interest 70% |
| SRPT | Sarepta Therapeutics | 85.9 | A | clinical activity 100%, short interest 70%, dilution risk 48% |
Recent Grade-Change Queue
- UCBNV (UCB SA) currently grades F with a 13.7/100 catalyst score. Main inputs: publication signal 75%, clinical activity 12%.
- SNY (Sanofi SA) currently grades D with a 46.9/100 catalyst score. Main inputs: clinical activity 62%, dilution risk 12%, short interest 10%.
- RCUS (Arcus Biosciences) currently grades C with a 61.6/100 catalyst score. Main inputs: clinical activity 67%, dilution risk 50%, short interest 50%.
- PBYI (Puma Biotechnology Inc) currently grades C with a 54.0/100 catalyst score. Main inputs: publication signal 100%, clinical activity 62%, short interest 50%.
- OPK (OPKO Health, Inc.) currently grades F with a 21.7/100 catalyst score. Main inputs: short interest 50%, dilution risk 27%, clinical activity 17%.
- BDRX (Biodexa Pharmaceuticals plc) currently grades F with a 28.6/100 catalyst score. Main inputs: dilution risk 47%, clinical activity 25%, short interest 10%.
- ICLR (ICON plc) currently grades F with a 20.5/100 catalyst score. Main inputs: clinical activity 38%, dilution risk 10%, short interest 10%.
- EXEL (Exelixis Inc) currently grades F with a 26.6/100 catalyst score. Main inputs: short interest 50%, clinical activity 29%, dilution risk 10%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.